The case for & against
Bull & Bear analysis
Bullish
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is a clinical-stage biotechnology company focused on developing novel drug antibody conjugates to address significant unmet medical needs in the prevention and treatment of influenza, particularly in high-risk populations. Cidara's lead asset, CD388, aims to revolutionize the flu prevention landscape by providing a universal antiviral alternative, mitigating the limitations of current vaccines. As it progresses toward pivotal Phase III trials, Cidara stands at the forefront of a critical and evolving healthcare market.
Bull says
- ↑Analysts rate CDTX 'Buy' with $7-9B peak revenue potential for CD388
- ↑Breakthrough Therapy designation offers expedited FDA review and guidance
- ↑Accelerated Phase III plan targets market entry by 2026
- ↑$476M cash runway supports trials; potential BARDA funding boosts liquidity
- ↑CD388 addresses >20M high-risk patients, with expansion into broader populations
- ↑Proprietary Cloudbreak platform positions CD388 as a universal flu antiviral
Bear says
- ↓No approved products and negative earnings (P/E –18.8) fuel cash-burn concerns
- ↓Significant FDA approval risks; trial-design alignment may delay Phase III start
- ↓Dependence on BARDA grants for manufacturing scaling adds funding uncertainty
- ↓Vaccine competition and low flu vaccination rates could hinder CD388 uptake
- ↓Market cap ~$345M vs. high R&D spend increases dilution risk
- ↓Commodity perception of flu therapeutics may limit premium pricing
Investment themes with CDTX
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 09-08-2026bullish
Transcript signals
Bull points
- we see a substantial opportunity in that high-risk comorbid as well as the immune-compromised populations.
- we expect to announce top-line data by the end of June.
- Dependent on the results of our Phase IIb study and our regulatory discussions, we expect to initiate a Phase III study in the spring of 2026 in the southern hemisphere.
Bear points
- the higher than expected breakthrough infection rates here?
Read full transcript analysis ›